Meet our Alumni: Evotion
Evotion solves the problem of monitoring a child's health status through continuous follow-up of biometric parameters, also providing reliable data to pediatricians, and offering constant monitoring during sleep that enables parents to prevent cardiorespiratory problems, the leading cause of death in children 1-12 months.
Co-founded by Alessio Pietracupa, CEO, and Alessandro M. Avitabile, Head of Marketing & Sales, the company is ready to make some big moves during the 2022 program. Get to know them in the following interview featuring highlights from their experience with VITA and discover how they are striving to transform health with their innovative solutions.
What was the inspiration behind your company and how will your solution change the current healthcare scenario?
The purpose behind our company is to create an environment in which innovation is created based on careful analysis of the medical-scientific sector and market. It was from these two worlds coming together that Evotion, and more importantly Momi, our first product, were born. Momi is a supportive device for families and medical professionals, ensuring continuous health status monitoring of children and reliable data analysis, with a specific focus on monitoring cardio-respiratory parameters during sleep. This facilitates better follow-up activities and reduces unnecessary hospitalizations, and visits.
What are you hoping to achieve during the VITA Accelerator Program?
The VITA accelerator program is an opportunity to receive expert support that allows us to broaden our knowledge of the industry and better structure our startup's processes. This will make us grow faster and ultimately refine Momi, ensuring a medically relevant product.
Which program sessions or events have you found most helpful for your company? Could you highlight some milestones or connections made during your time with VITA?
It would be really difficult to identify just a few. In fact, all sessions, both plenary and 1:1, and also the events, have been a great opportunity to improve our knowledge and analyze the dynamics of the digital health market from new perspectives. The most important milestone since the start of the program has been the establishment of a pre-clinical trial. Indeed, with the guidance from the VITA mentors, we have created an additional step in product validation that will take place at IRCCS Neuromed's neonatal facilities.
In addition to the connections made with mentors and program partners, our participation in Frontiers Health Global Conference enabled us to connect with important VCs and get to know other entrepreneurs with whom important synergies will surely arise, empowering us to develop our products with new perspectives.
What is the next big move your company will take and where would you like to see yourselves in the next 5 years?
Our next big move, once the scientific validation phase is over, will be to launch Momi on the Italian market in 2023 and then aim for medical certification of the device. In the next five years, we want to position ourselves as one of the main players in our market area by continuously improving our product and expanding both in the Italian and international scene. Thus, exporting an all-Italian digital health solution.
More info at: www.evotion.it